Pharmaceutical organization Developing new antiretroviral drugs for HIV/AIDS patients infected with the hepatitis C virus
Today (November 30, 2022) PhD Nantakan Suwanpidokkul Government Pharmaceutical Organization (GPO) Deputy Director discusses GPO research and development for people living with HIV/AIDS. On World AIDS Day, December 1, the Ministry of Public Health recognizes the importance of developing research into antiretroviral drugs for HIV/AIDS patients. continuously come up with the development of antiretroviral drugs to keep up with the situation and new therapeutic guidelines as well as drug development both in single drug formulations and combination drug formulations for adults and children Taking into account the convenience of the patient taking the drug continuously. to prevent drug resistance Including the development of drug efficacy to cover treatment even among patients with drug resistance.
The deputy director of the PPP said that in the past it was found that there were people infected with HIV / AIDS. along with many hepatitis C infections not having access to drug therapy. Because it is a drug that must be imported, which has a high price. Therefore, DOH started the research and development of the first generic anti-HCV drug since 2012, namely ribavirin tablets, 400 and 200 mg, used in combination with pecinterfer Ron injection (pegylated interferon; Peg-IFN ). It makes the patient uncomfortable in administering the drug. Therefore he switched to drug use in the form of oral drugs The Ministry of Public Health then researched and developed a well-known combination drug formula. GPO-Hep C tablets, which are a combination of 400mg Sofosbuvir tablets and Velpatasvir tablets Pangenotypic direct-acting antiviral agents (DAAs) are available for the treatment of all strains of hepatitis C virus infection. Increase the convenience of taking medicines for patients. Resulting in better treatment efficiency and reducing the problem of drug resistance. Reducing the number of pills to be taken from 2 tablets 1 time per day from the original formula of the drug to 1 tablet 1 time per day. It has been used to treat infected people and patients in the national health security system. and patients in the social security system can use the hospital service according to the right to free treatment
Dr. Nuntakarn said that developing such drugs is like a gift that Apor.M. is determined to do to infected people and patients. To have access to treatment effectively and equitably, in line with the concept of holding the “Thian Song Jai” event on World AIDS Day on December 1, 2022, which the Thai Red Cross has scheduled annually. Between 1 and 3 December 2022 to raise awareness of the problem of AIDS. and cooperation, prevention, correction, as well as understanding building of infected people Organizing the event under the concept of “EQualize, make it equal” at Rattana Wittayapat Building, M1 Floor, Chulalongkorn Hospital, Thai Red Cross Society, where the PPP participated in the presentation of the development of new antiviral drugs. Provide infected people and Thai patients with access to effective medicines and treatments. leading to a better quality of life
